A Phase 3 interventional study of imatinib mesylate and Placebo in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 95 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 5 in phase 3, and was the 2nd registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 15 more countries
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6
First in 2006; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 27 across the 12 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
Key Inclusion criteria
Key Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted.
Drug: imatinib mesylate
Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive already approved PAH treatments.
Drug: Placebo
Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
Placebo to imatinib 100 mg film coated tablets
Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks
This standardized walk course was 30 meters in length. During the walk the participant was connected to a portable pulse oximeter via a finger probe. Participants were instructed to walk at a comfortable speed for as far as they could manage in 6 minutes. The total distance walked (in meters) was recorded. Results were compared between the 2 groups.
Time frame: 24 weeks
Clinical Worsening Comparing Imatinib Versus Placebo for Adjudicated Cases
Clinical worsening per participant was measured by the onset of any adjudicated event (all cause mortality; overnight hospitalization for worsening of Pulmonary Arterial Hypertension (PAH); worsening of WHO functional class by one level; 15% decline in Six Minute Walk Distance (6MWD) measured on two consecutive occasions) at 24 weeks treatment, comparing imatinib to placebo groups. A cox regression analysis model was used.
Time frame: 24 weeks
Change From Baseline in Right Atrial Pressure
Change from baseline in right atrial pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The right atrial pressure was assessed when the participant was in a stable hemodynamic rest state. A higher right atrial pressure number indicates worsening.
Time frame: baseline and week 24
Change From Baseline in Mean Pulmonary Arterial Pressure
Change from baseline in mean pulmonary arterial pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The mean pulmonary arterial pressure was assessed when the participant was in a stable hemodynamic rest state. A higher mean pulmonary arterial pressure number indicates worsening.
Time frame: baseline and week 24
Change From Baseline in Mean Pulmonary Capillary Wedge Pressure
Change from baseline in mean pulmonary capillary wedge pressure (mmHg)was measured via right heart catheterization according to the local hospital procedures. The right atrial mean pulmonary capillary wedge pressure was assessed when the participant was in a stable hemodynamic rest state.
Time frame: baseline and week 24
Change From Baseline in Systemic Vascular Resistance
Change from baseline in systemic vascular resistance (dynes\*sec\*cm\^-5) was measured via right heart catheterization according to the local hospital procedures. The systemic vascular resistance was assessed when the participant was in a stable hemodynamic rest state. Reduction from baseline in mean systemic vascular resistance indicates improvement.
Time frame: baseline and week 24
Change From Baseline in Pulmonary Vascular Resistance
Change from baseline in pulmonary vascular resistance (dynes\*sec\*cm\^-5) was measured via right heart catheterization according to the local hospital procedures. The pulmonary vascular resistance was assessed when the participant was in a stable hemodynamic rest state. Reduction from baseline in pulmonary vascular resistance indicates improvement.
Time frame: baseline and week 24
Change From Baseline in Pulmonary Resistance Index
Change from baseline in pulmonary resistance index (dynes\*sec\*cm\^-5/m2) was measured via right heart catheterization according to the local hospital procedures. The pulmonary resistance index was assessed when the participant was in a stable hemodynamic rest state. A reduction from baseline in pulmonary resistance index indicates improvement.
Time frame: baseline and week 24
Change From Baseline in Cardiac Output
Change from baseline in cardiac output (L/min) was measured via right heart catheterization according to the local hospital procedures. The cardiac output was assessed when the participant was in a stable hemodynamic rest state. An increase from baseline (higher number) in cardiac output indicates improvement.
Time frame: 24 weeks
Change From Baseline in Systolic Arterial Blood Pressure
Change from baseline in systolic arterial blood pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The systolic arterial blood was assessed when the participant was in a stable hemodynamic rest state.
Time frame: baseline and week 24
Change From Baseline in Diastolic Arterial Blood Pressure
Change from baseline in diastolic arterial blood pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The diastolic arterial blood pressure was assessed when the participant was in a stable hemodynamic rest state.
Time frame: baseline and week 24
Change From Baseline in Heart Rate
Change from baseline in heart rate (bpm) was measured via right heart catheterization according to the local hospital procedures. The heart rate was assessed when the participant was in a stable hemodynamic rest state.
Time frame: 24 weeks
Change in Borg Dyspnea Score During 6-minute Walk Test
Change in Borg scale was measured at different time points at week 24. The Borg Scale consists of scale range of 0 to 10. Participants pointed to indicate their level of dyspnea before and at the end of exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness). A reduction in this score indicates an improvement.
Time frame: week 24
Covariance of End of Study CAMPHOR Score
The CAMPHOR test consists of 65 items and 3 scales. Two scales measure Health Related Quality of Life. 1) Symptoms: consists of 25 items measuring loss or abnormality of psychological, physiological or anatomical structure or function; further sub-divided into 3 subscales (energy, breathlessness and mood), 2) Disability: consists of 15 items measuring any restriction or lack of ability to perform an activity. 3) Quality of Life (QOL): consists of 25 items defining how individuals perceived ability and capacity to satisfy their needs. The 25-item symptom and QOL scales score from 0-25 where a higher score indicates the presence of more symptoms and poor QOL, respectively. The 15-item functioning scale scores 0-30; a higher score indicates poor functioning.
Time frame: Week 24
Plasma Concentration of QTI571 200 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant
Blood samples were taken from each subject participating in the study (placebo group and active treatment group) once predose and once between 0 hour to 3 hour post dose at day 1 (baseline), day 14, day 28 and day 168. The parent compound QTI571 and its active metabolite, GCP74588, were measured in plasma by validated liquid chromatography-mass spectrometry (HPLC-MS/MS) assay.
Time frame: predose and between 0 hour to 3 hour post dose at day 1, day 14, day 28 and day 168
Plasma Concentration of QTI571 400 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant
Blood samples were taken from each subject participating in the study (placebo group and active treatment group) once predose and once between 0 hour to 3 hour post dose at day 1 (baseline), day 14, day 28 and day 168. The parent compound QTI571 and its active metabolite, GCP74588, were measured in plasma by validated liquid chromatography-mass spectrometry (HPLC-MS/MS) assay.
Time frame: predose and between 0 hour to 3 hour post dose at day 1, day 14, day 28 and day 168
Overall, 326 participants were screened, 202 participants were randomized (103 to Imatinib and 99 to placebo). Out of 202 participants randomized 201 participants received study drug treatment (103 received imatinib mesylate, 98 received placebo). One participant was randomized to the placebo group but did not receive any study treatment.
| Milestone | Imatinib Mesylate | Placebo |
|---|---|---|
| Started | 103 | 99 |
| Completed | 69 | 81 |
| Not completed | 34 | 18 |
| Withdrew: Adverse event | 27 | 7 |
| Withdrew: Lack of efficacy | 1 | 5 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Abnormal labs | 1 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Administration problem | 0 | 1 |
This standardized walk course was 30 meters in length. During the walk the participant was connected to a portable pulse oximeter via a finger probe. Participants were instructed to walk at a comfortable speed for as far as they could manage in 6 minutes. The total distance walked (in meters) was recorded. Results were compared between the 2 groups.
| meters | Imatinib | Placebo |
|---|---|---|
| Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks | 382.94 ± 9.790 | 351.18 ± 9.834 |
Clinical worsening per participant was measured by the onset of any adjudicated event (all cause mortality; overnight hospitalization for worsening of Pulmonary Arterial Hypertension (PAH); worsening of WHO functional class by one level; 15% decline in Six Minute Walk Distance (6MWD) measured on two consecutive occasions) at 24 weeks treatment, comparing imatinib to placebo groups. A cox regression analysis model was used.
| percentage of participants | Imatinib | Placebo |
|---|---|---|
| Clinical Worsening Comparing Imatinib Versus Placebo for Adjudicated Cases | 35.9 | 32.7 |
Change from baseline in right atrial pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The right atrial pressure was assessed when the participant was in a stable hemodynamic rest state. A higher right atrial pressure number indicates worsening.
| mm Hg | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Right Atrial Pressure | -1.02 ± 0.851 | 0.68 ± 0.855 |
Change from baseline in mean pulmonary arterial pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The mean pulmonary arterial pressure was assessed when the participant was in a stable hemodynamic rest state. A higher mean pulmonary arterial pressure number indicates worsening.
| mm Hg | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Mean Pulmonary Arterial Pressure | -3.54 ± 1.585 | 1.63 ± 1.586 |
Change from baseline in mean pulmonary capillary wedge pressure (mmHg)was measured via right heart catheterization according to the local hospital procedures. The right atrial mean pulmonary capillary wedge pressure was assessed when the participant was in a stable hemodynamic rest state.
| mm Hg | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Mean Pulmonary Capillary Wedge Pressure | 0.92 ± 0.693 | -0.05 ± 0.701 |
Change from baseline in systemic vascular resistance (dynes\*sec\*cm\^-5) was measured via right heart catheterization according to the local hospital procedures. The systemic vascular resistance was assessed when the participant was in a stable hemodynamic rest state. Reduction from baseline in mean systemic vascular resistance indicates improvement.
| dynes*sec*cm^-5 | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Systemic Vascular Resistance | -467.84 ± 78.577 | -88.10 ± 77.183 |
Change from baseline in pulmonary vascular resistance (dynes\*sec\*cm\^-5) was measured via right heart catheterization according to the local hospital procedures. The pulmonary vascular resistance was assessed when the participant was in a stable hemodynamic rest state. Reduction from baseline in pulmonary vascular resistance indicates improvement.
| dynes*sec*cm^-5 | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Pulmonary Vascular Resistance | -366.47 ± 67.673 | 12.12 ± 68.963 |
Change from baseline in pulmonary resistance index (dynes\*sec\*cm\^-5/m2) was measured via right heart catheterization according to the local hospital procedures. The pulmonary resistance index was assessed when the participant was in a stable hemodynamic rest state. A reduction from baseline in pulmonary resistance index indicates improvement.
| dynes*sec*cm^-5/m2 | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Pulmonary Resistance Index | -221.29 ± 47.355 | 21.92 ± 48.247 |
Change from baseline in cardiac output (L/min) was measured via right heart catheterization according to the local hospital procedures. The cardiac output was assessed when the participant was in a stable hemodynamic rest state. An increase from baseline (higher number) in cardiac output indicates improvement.
| Liters/minute | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Cardiac Output | 1.17 ± 0.182 | 0.29 ± 0.186 |
Change from baseline in systolic arterial blood pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The systolic arterial blood was assessed when the participant was in a stable hemodynamic rest state.
| mm Hg | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Systolic Arterial Blood Pressure | -2.92 ± 2.298 | -1.15 ± 2.227 |
Change from baseline in diastolic arterial blood pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The diastolic arterial blood pressure was assessed when the participant was in a stable hemodynamic rest state.
| mm Hg | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Diastolic Arterial Blood Pressure | -3.81 ± 1.958 | -1.48 ± 1.909 |
Change from baseline in heart rate (bpm) was measured via right heart catheterization according to the local hospital procedures. The heart rate was assessed when the participant was in a stable hemodynamic rest state.
| bpm | Imatinib | Placebo |
|---|---|---|
| Change From Baseline in Heart Rate | 0.38 ± 12.63 | 0.73 ± 2.255 |
Change in Borg scale was measured at different time points at week 24. The Borg Scale consists of scale range of 0 to 10. Participants pointed to indicate their level of dyspnea before and at the end of exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness). A reduction in this score indicates an improvement.
| units on a scale | Imatinib | Placebo |
|---|---|---|
| Resting (n= 86 imatinib; 89 placebo) | -0.06 ± 1.097 | -0.12 ± 1.142 |
| End of test (n= 92 imatinib; 91 placebo) | -0.38 ± 2.009 | -0.24 ± 2.093 |
| 2 min after end (n= 82 imatinib; 81 placebo) | -0.37 ± 1.409 | -0.18 ± 1.550 |
| End of test - Resting (n= 81 imatinib; 81 placebo) | -0.24 ± 1.193 | -0.29 ± 1.279 |
| 2 min after end - end of test (n= 82 ima; 81plb) | -0.07 ± 1.533 | -0.03 ± 1.743 |
The CAMPHOR test consists of 65 items and 3 scales. Two scales measure Health Related Quality of Life. 1) Symptoms: consists of 25 items measuring loss or abnormality of psychological, physiological or anatomical structure or function; further sub-divided into 3 subscales (energy, breathlessness and mood), 2) Disability: consists of 15 items measuring any restriction or lack of ability to perform an activity. 3) Quality of Life (QOL): consists of 25 items defining how individuals perceived ability and capacity to satisfy their needs. The 25-item symptom and QOL scales score from 0-25 where a higher score indicates the presence of more symptoms and poor QOL, respectively. The 15-item functioning scale scores 0-30; a higher score indicates poor functioning.
| units on a scale | Imatinib | Placebo |
|---|---|---|
| Symptoms score | 7.93 ± 1.372 | 9.03 ± 1.431 |
| Activity score | 8.99 ± 1.177 | 10.55 ± 1.223 |
| Quality of life score | 7.45 ± 1.026 | 7.13 ± 1.066 |
Blood samples were taken from each subject participating in the study (placebo group and active treatment group) once predose and once between 0 hour to 3 hour post dose at day 1 (baseline), day 14, day 28 and day 168. The parent compound QTI571 and its active metabolite, GCP74588, were measured in plasma by validated liquid chromatography-mass spectrometry (HPLC-MS/MS) assay.
| ng/mL | Imatinib 200 mg | GCP74588 |
|---|---|---|
| Day 1 - predose (n=77 imat; n=77 GCP) | 0 ± 0 | 0 ± 0 |
| Day 1 - 0-3h post-dose (n=77 imat; n=77 GCP) | 471.9 ± 560.1 | 61.8 ± 77.6 |
| Day 14 - predose (n=18 imat; n=18 GCP) | 579.6 ± 384.9 | 178.8 ± 122.8 |
| Day 14 - 0-3h post-dose (n=19 imat; n=19 GCP) | 1005.7 ± 665.6 | 233.8 ± 170.9 |
| Day 28 - predose (n=20 imat; n=20 GCP) | 658.8 ± 450.3 | 228.6 ± 121.4 |
| Day 28 - 0-3h post-dose (n=19 imat; n=19 GCP) | 1438.6 ± 924.4 | 323.9 ± 150.6 |
| Day 168 predose (n=24 imat; n=24 GCP) | 398.6 ± 415.5 | 126.6 ± 83.3 |
| Day 168- 0-3h post-dose (n=23 imat; n=23 GCP) | 710.8 ± 639.7 | 166.1 ± 103.1 |
Blood samples were taken from each subject participating in the study (placebo group and active treatment group) once predose and once between 0 hour to 3 hour post dose at day 1 (baseline), day 14, day 28 and day 168. The parent compound QTI571 and its active metabolite, GCP74588, were measured in plasma by validated liquid chromatography-mass spectrometry (HPLC-MS/MS) assay.
| ng/mL | Imatinib 400 mg | GCP74588 |
|---|---|---|
| Day 1 - predose (n=12 imat; n=12 GCP) | 0 ± 0 | 0 ± 0 |
| Day 1 - 0-3h post-dose (n=13 imat; n=13 GCP) | 843.2 ± 788.9 | 109.9 ± 132.4 |
| Day 14 - predose (n=62 imat; n=62 GCP) | 516.5 ± 405.2 | 155.1 ± 101.1 |
| Day 14 - 0-3h post-dose (n=62 imat; n=62 GCP) | 1172.8 ± 1088.9 | 233.7 ± 165.6 |
| Day 28 - predose (n=55 imat; n=55 GCP) | 829.8 ± 482.6 | 248.2 ± 125.2 |
| Day 28 - 0-3h post-dose (n=58 imat; n=58 GCP) | 1335.3 ± 817.9 | 320.7 ± 154.8 |
| Day 168 predose (n=36 imat; n=36 GCP) | 869.9 ± 407.8 | 241.4 ± 91.9 |
| Day 168- 0-3h post-dose (n=35 imat; n=35 GCP) | 1616.1 ± 787.6 | 348.0 ± 119.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib | — | 45/103 (43.7%) | 96/103 (93.2%) |
| Placebo | — | 29/98 (29.6%) | 80/98 (81.6%) |
| Event | Imatinib | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/103 | 1/98 |
| Oedema peripheralGeneral disorders | 6/103 | 0/98 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/103 | 2/98 |
| SyncopeNervous system disorders | 1/103 | 5/98 |
| PresyncopeNervous system disorders | 5/103 | 0/98 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 4/103 | 4/98 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 2/103 | 4/98 |
| DiarrhoeaGastrointestinal disorders | 3/103 | 2/98 |
| Device related infectionInfections and infestations | 3/103 | 0/98 |
| Right ventricular failureCardiac disorders | 2/103 | 2/98 |
| Event | Imatinib | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 56/103 | 23/98 |
| Oedema peripheralGeneral disorders | 41/103 | 20/98 |
| DiarrhoeaGastrointestinal disorders | 33/103 | 18/98 |
| Periorbital oedemaEye disorders | 30/103 | 7/98 |
| VomitingGastrointestinal disorders | 30/103 | 10/98 |
| HeadacheNervous system disorders | 25/103 | 22/98 |
| NasopharyngitisInfections and infestations | 18/103 | 19/98 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/103 | 15/98 |
| HypokalaemiaMetabolism and nutrition disorders | 14/103 | 3/98 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 13/103 | 11/98 |
Age set includes all randomized participants (202). Gender set includes all treated participants (201). One participant was randomized to placebo but did not receive stuy drug.
| Age, Continuous(years) | Imatinib Mesylate | Placebo | Total |
|---|---|---|---|
| Mean | 50.0 ± 15.33 | 46.5 ± 13.60 | 48.3 ± 14.59 |
| Gender(participants) | Imatinib Mesylate | Placebo | Total |
|---|---|---|---|
| Female | 83 | 79 | 162 |
| Male | 20 | 19 | 39 |
The record gives a start of Sep 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 2 years 2 months after primary completion. A results delay was requested in Apr 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Pulmonary Arterial Hypertension →